Get the Stockscreener App
206.27
0.17%
-0.34
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $206.27, with a volume of 785.29K.
It is down -0.17% in the last 24 hours and up +121.89% over the past month.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$206.61
Open:
$206.745
24h Volume:
785.29K
Relative Volume:
0.14
Market Cap:
$319.71B
Revenue:
$58.80B
Net Income/Loss:
$10.24B
P/E Ratio:
62.91
EPS:
3.2788
Net Cash Flow:
$8.98B
1W Performance:
-1.16%
1M Performance:
+121.89%
6M Performance:
+158.95%
1Y Performance:
+173.54%
1-Day Range:
$205.30
$207.55
1-Week Range:
$204.05
$209.35
52-Week Range:
$61.24
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
206.23 | 320.30B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
LLY
Lilly Eli Co
|
1,032.60 | 983.12B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
244.91 | 593.51B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
227.45 | 403.74B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
167.65 | 318.87B | 54.72B | 14.02B | 15.32B | 7.1855 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
AstraZeneca’s Soriot Rewarded With $23m Pay But Still Lags Behind US Peers - Citeline News & Insights
AstraZeneca Advances Subcutaneous Durvalumab Study, Targeting More Convenient Cancer Care - TipRanks
Astrazeneca files 2025 annual report on Form 20-F with SEC - Investing.com
AstraZeneca PLCFiling of Form 20-F with SEC - Research Tree
Assessing AstraZeneca (LSE:AZN) Valuation After Strong Recent Share Price Momentum - simplywall.st
AstraZeneca Drug Price Challenge Falls Short In Hawaii - Law360
AstraZeneca boss Pascal Soriot nets £17.7m in pay and bonuses for 2025 - Yahoo Finance UK
AstraZeneca’s CLARITY-Gastric 02 Trial Targets New Front in Stomach Cancer - TipRanks
AstraZeneca Fails in Bid to Halt Hawaii 340B Drug Delivery Law - Bloomberg Law News
AstraZeneca publishes 2025 annual financial report and sets AGM for April - Investing.com
AstraZeneca announces board changes as Nazneen Rahman to retire in April By Investing.com - Investing.com South Africa
AstraZeneca announces board changes as Nazneen Rahman to retire in April - Investing.com UK
AstraZeneca PLC Announces Directorate And Committee Changes, Effective April 9, 2026 - marketscreener.com
AstraZeneca boosts CEO Soriot's pay to about $24 million for 2025 - marketscreener.com
AstraZeneca announces retirement of non-executive director Nazneen Rahman - marketscreener.com
AstraZeneca : Directorate change - marketscreener.com
FDA Gives Green Light to AstraZeneca's All-Oral Calquence-Venetoclax Combo for CLL - StockInvest.us
Fact Check: No, AstraZeneca Vaccine Does Not Mean 'Path to Death' - Tempo.co English
AstraZeneca PLC (LON:AZN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026? - The Globe and Mail
AstraZeneca (AZN) Gains FDA Orphan Designation for Follicular Ly - GuruFocus
AstraZeneca Secures US Approval For Fixed-duration Calquence Regimen In CLL - DirectorsTalk Interviews
AstraZeneca receives US approval for fixed-duration Calquence and venetoclax combination in CLL By Investing.com - Investing.com South Africa
Woodley Farra Manion Portfolio Management Inc. Lowers Holdings in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Shares Purchased by Synovus Financial Corp - MarketBeat
Wealthcare Advisory Partners LLC Buys 19,612 Shares of AstraZeneca PLC $AZN - MarketBeat
FDA Approval For AbbVie/AstraZeneca's Combination Treatment Could Set New Standard For Slow Growing Blood Cancer - Benzinga
AstraZeneca receives US approval for fixed-duration Calquence and venetoclax combination in CLL - Investing.com Nigeria
AstraZeneca Says US FDA Approves Calquence Combo for Certain Blood Cancer Patients - marketscreener.com
AstraZeneca's (AZN) Calquence Gains FDA Approval for New Leukemi - GuruFocus
AstraZeneca's (AZN) Calquence Gains FDA Approval for Leukemia Tr - GuruFocus
China Universal Asset Management Co. Ltd. Has $10.25 Million Holdings in AstraZeneca PLC $AZN - MarketBeat
Factory Mutual Insurance Co. Acquires Shares of 57,852 AstraZeneca PLC $AZN - MarketBeat
Glucagon-like Peptide 1 (GLP-1) Market Report 2026-2035: Market to Reach $33.26 Billion by 2030 - GlobeNewswire Inc.
US Approves AstraZeneca's Combination Treatment for Leukemia, Lymphoma - marketscreener.com
AstraZeneca announces fixed-duration Calquence combo approved in US - marketscreener.com
AstraZeneca’s Calquence combo wins US approval for blood cancer By Investing.com - Investing.com UK
Daiichi Sankyo and AstraZeneca get EU validation for Enhertu use - marketscreener.com
AstraZeneca Prevails In Whistleblower Suit 9th Circ. Revived - Law360
AstraZeneca Targets Hidden COPD Burden in Heart Clinics: What Investors Should Watch - TipRanks
Why AstraZeneca PLC (AZN) is One of the Best Immunotherapy Stocks to Buy According to Hedge Funds - Finviz
AstraZeneca PLC $AZN Shares Sold by Ontario Teachers Pension Plan Board - MarketBeat
Burling Wealth Partners LLC Sells 11,537 Shares of AstraZeneca PLC $AZN - MarketBeat
EMA Validates Enhertu Application for AstraZeneca (AZN) - GuruFocus
AstraZeneca, Daiichi Sankyo EU Application Validated for Breast Cancer Treatment - marketscreener.com
JPMorgan Chase & Co. Increases Stake in AstraZeneca PLC $AZN - MarketBeat
Revenue of AstraZeneca from 2006 to 2024 - Statista
FDA Implements New Policy for Drug Approval Requirements Impacti - GuruFocus
FDA Policy Shift: Impact on AstraZeneca (AZN) and Pharmaceuticals - GuruFocus
AstraZeneca stock hits all-time high at 212.37 USD By Investing.com - Investing.com South Africa
AstraZeneca (AZN) at the center of serious analyst attention - MSN
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
1.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):